» Articles » PMID: 28392281

Human Stem Cell Modeling in Neurofibromatosis Type 1 (NF1)

Overview
Journal Exp Neurol
Specialty Neurology
Date 2017 Apr 11
PMID 28392281
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The future of precision medicine is heavily reliant on the use of human tissues to identify the key determinants that account for differences between individuals with the same disorder. This need is exemplified by the neurofibromatosis type 1 (NF1) neurogenetic condition. As such, individuals with NF1 are born with a germline mutation in the NF1 gene, but may develop numerous distinct neurological problems, ranging from autism and attention deficit to brain and peripheral nerve sheath tumors. Coupled with accurate preclinical mouse models, the availability of NF1 patient-derived induced pluripotent stem cells (iPSCs) provides new opportunities to define the critical factors that underlie NF1-associated nervous system disease pathogenesis and progression. In this review, we discuss the generation and potential applications of iPSC technology to the study of NF1.

Citing Articles

Pediatric Tumors as Disorders of Development: The Case for In Vitro Modeling Based on Human Stem Cells.

Clairmont C, Gell J, Lau C Cancer Control. 2024; 31:10732748241270564.

PMID: 39118322 PMC: 11311176. DOI: 10.1177/10732748241270564.


An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies.

Chen Y, Yu J, Ge S, Jia R, Song X, Wang Y Invest Ophthalmol Vis Sci. 2024; 65(6):8.

PMID: 38837168 PMC: 11160950. DOI: 10.1167/iovs.65.6.8.


Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.

Darle A, Mahiet T, Aubin D, Doyen M, El Kassar L, Parfait B Front Cell Dev Biol. 2024; 12:1359561.

PMID: 38481529 PMC: 10935092. DOI: 10.3389/fcell.2024.1359561.


Characterization of Dental Pulp Stem Cell Populations in the Teeth of Patients With Neurofibromatosis Type 1 - Therapeutic Potential for Bone Tissue Engineering.

Yan M, Wang W, Speth U, Kluwe L, Fuest S, Gosau M In Vivo. 2023; 37(2):548-558.

PMID: 36881087 PMC: 10026680. DOI: 10.21873/invivo.13113.


Malignant peripheral nerve sheath tumor: models, biology, and translation.

Somatilaka B, Sadek A, McKay R, Le L Oncogene. 2022; 41(17):2405-2421.

PMID: 35393544 PMC: 9035132. DOI: 10.1038/s41388-022-02290-1.


References
1.
Kreitzer F, Salomonis N, Sheehan A, Huang M, Park J, Spindler M . A robust method to derive functional neural crest cells from human pluripotent stem cells. Am J Stem Cells. 2013; 2(2):119-31. PMC: 3708511. View

2.
Xie F, Ye L, Chang J, Beyer A, Wang J, Muench M . Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res. 2014; 24(9):1526-33. PMC: 4158758. DOI: 10.1101/gr.173427.114. View

3.
Zhu Y, Harada T, Liu L, Lush M, Guignard F, Harada C . Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development. 2005; 132(24):5577-88. PMC: 2760350. DOI: 10.1242/dev.02162. View

4.
Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, Hochedlinger K . A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell. 2008; 3(3):340-5. PMC: 3987901. DOI: 10.1016/j.stem.2008.08.003. View

5.
Dai P, Harada Y, Takamatsu T . Highly efficient direct conversion of human fibroblasts to neuronal cells by chemical compounds. J Clin Biochem Nutr. 2015; 56(3):166-70. PMC: 4454078. DOI: 10.3164/jcbn.15-39. View